EU nod for Novo’s long-acting haemophilia drug

7th June 2017 Uncategorised 0

Novo Nordisk says it expects to launch its long-acting haemophilia B drug Refixia in the European Union in the fourth quarter of this year after receiving a green light from regulators.

More: EU nod for Novo’s long-acting haemophilia drug
Source: News